(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 October 2014 (09.10.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/164709 A3

(51) International Patent Classification:
C12P 21/08 (2006.01) *C07K 14/495* (2006.01)
A61K 39/00 (2006.01) *A61K 39/395* (2006.01)
C07K 16/22 (2006.01)

(21) International Application Number:
PCT/US2014/023274

(22) International Filing Date:
11 March 2014 (11.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/776,430 11 March 2013 (11.03.2013) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 500 Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **WEI, Ronnie**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **MOULIN, Aaron**; 151 Oregon Road, Ashland, Massachusetts 01721 (US). **MATHIEU, Magali**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **PAN, Clark**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **PARK, Sunghae**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **QIU, Huawei**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **MEYER, Mercedes K.** et al.; Drinker Biddle & Reath LLP, 1500 K Street, N.W., Suite 1100, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*


— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
24 December 2014

(54) Title: ENGINEERED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

FIG. 5



(57) Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.

WO 2014/164709 A3